YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025.
First Quarter 2025 Highlights:
U.S. GAAP Results (U.S. dollars in thousands, except for per share data) | ||
Q1 2025 | Q1 2024 | |
Revenues | $77,874 | $80,284 |
Gross Margins | 78 % | 80 % |
Net Income | $18,201 | $23,696 |
Earnings per Diluted Share | $0.26 | $0.28 |
*Non-GAAP Results (U.S. dollars in thousands, except for per share data) | ||
Q1 2025 | Q1 2024 | |
Gross Margins | 79 % | 80 % |
Net Income | $21,395 | $27,679 |
Earnings per Diluted Share | $0.31 | $0.32 |
*Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and related tax adjustments.
Management Comments
"In Q1 2025, our performance reflected continued pressure from a challenging macroeconomic environment and weakened consumer demand," said Moshe Mizrahy, Chief Executive Officer of InMode. "While these external factors impacted results, we remain focused on executing our strategy. This includes driving operational excellence, investing in innovation, and pursuing disciplined capital allocation."
"We are pleased with our international performance in Q1, particularly in Europe, where we achieved record revenue despite ongoing market headwinds. Looking forward, we believe the recent launch of our OptimasMAX, and Ignite platforms reinforces our commitment to innovation while offering the gold standard technology in aesthetics," Mizrahy concluded.
Yair Malca, Chief Financial Officer of InMode, added, "Our strong balance sheet provides the stability and flexibility to navigate near-term challenges while continuing to invest in our long-term growth and recruit the best talent in the industry. We're pleased to report that, earlier this month, we completed our fifth share repurchase program of 6.95 million shares approved by our board of directors in February 2025, for a total of $127 million, underscoring our commitment to disciplined capital allocation and returning value to shareholders. In fact, our total capital return to shareholders in the past 12 months was more than $412 million, executed via share repurchases representing approximately 27% of our share capital.
"As always, we continue to explore all avenues for disciplined capital allocation, including additional share repurchases, potential dividends, and strategic M&A opportunities. Our approach remains focused on maximizing long-term shareholder value while maintaining a strong and flexible balance sheet. In addition, international markets accounted for a larger share of total revenue while the U.S. continued to experience challenging headwinds, resulting in a 4%–5% decline in operating margins. We anticipate this trend will persist through the end of the year. Lastly, with U.S. tariffs at their current levels at 10%, we expect an impact of approximately 2%–3% on gross margins," Malca concluded.
First Quarter 2025 Financial Results
Total GAAP revenues for the first quarter of 2025 were $77.9 million, a decrease of 3% compared to $80.3 million in first quarter of 2024.
GAAP gross margin for the first quarter of 2025 was 78%, compared to a gross margin of 80% for the first quarter of 2024. *Non-GAAP gross margin for the first quarter of 2025 was 79%, compared to a gross margin of 80% for the first quarter of 2024.
GAAP operating margin for the first quarter of 2025 was 20%, compared to 23% in the first quarter of 2024. *Non-GAAP operating margin for the first quarter of 2025 was 23% compared to 27% for the first quarter of 2024. This decrease was primarily attributable to the increase in cost of goods and marketing activity due to launch of new products.
InMode reported GAAP net income of $18.2 million, or $0.26 per diluted share, in the first quarter of 2025, compared to $23.7 million, or $0.28 per diluted share, in the first quarter of 2024. On a *non-GAAP basis, InMode reported net income of $21.4 million, or $0.31 per diluted share, in the first quarter of 2025, compared to $27.7 million, or $0.32 per diluted share, in the first quarter of 2024.
As of March 31, 2025, InMode had cash and cash equivalents, marketable securities and short-term bank deposits of $512.9 million.
2025 Financial Outlook
Management provided an outlook for the full year of 2025 ending December 31, 2025. Based on our current estimates, management expects:
This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. See "Forward-Looking Statements" for additional information.
*Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and related tax adjustments.
The Current Situation in Israel
Regarding the current situation in Israel, Israel and Hamas agreed to a ceasefire agreement; the first phase of such ceasefire began in January 2025. During March 2025, the ceasefire collapsed. Since its collapse, fighting has been carried out at low intensity, amid international attempts to end the war. We remain confident in our ability to continue our R&D and manufacturing activities while maintaining the safety and well-being of our employees.
Use of Non-GAAP Financial Measures
In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, non-GAAP operating margin. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.
Conference Call Information
Mr. Moshe Mizrahy, Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer, Mr. Yair Malca, Chief Financial Officer will host a conference call today, April 28, 2025, at 8:30 a.m. Eastern Time to discuss the first quarter 2025 financial results.
The Company encourages participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10198516/fede138cb8.
Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.
For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.
U.S. Toll-Free Dial-in Number: 1-833-316-0562
Israel Toll- Free Dial-in Number: 1-80-921-2373
International Dial-in Number: 1-412-317-5736
Webcast URL Link
At:
8:30 a.m. Eastern Time
5:30 a.m. Pacific Time
The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from April 28, 2025, at 12 p.m. Eastern Time to May 12, 2025, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers:
Replay Dial-in U.S TOLL-FREE: 1-877-344-7529
Replay Dial-in Canada TOLL-FREE: 1-855-669-9658
Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088
Replay Pin Number: 3039661
To access the replay using an international dial-in number, please select the link below: https://services.choruscall.com/ccforms/replay.html
A replay of the conference call will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
Forward-Looking Statements
The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2025 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 4, 2025, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.
Company Contact: Yair Malca Chief Financial Officer Phone: (949) 305-0108 Email: This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Relations Contact: Miri Segal MS-IR LLC Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
INMODE LTD. | ||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME | ||
(U.S. dollars in thousands, except for per share data) | ||
(Unaudited) | ||
Three months ended | ||
2025 | 2024 | |
REVENUES | 77,874 | 80,284 |
COST OF REVENUES | 16,963 | 16,365 |
GROSS PROFIT | 60,911 | 63,919 |
OPERATING EXPENSES: | ||
Research and development | 2,895 | 3,518 |
Sales and marketing | 39,727 | 39,795 |
General and administrative | 2,671 | 2,514 |
TOTAL OPERATING EXPENSES | 45,293 | 45,827 |
OPERATIONS INCOME | 15,618 | 18,092 |
Finance income, net | 6,859 | 7,984 |
INCOME BEFORE INCOME TAXES | 22,477 | 26,076 |
INCOME TAXES | 4,276 | 2,380 |
NET INCOME | 18,201 | 23,696 |
EARNINGS PER SHARE: | ||
Basic | 0.26 | 0.28 |
Diluted | 0.26 | 0.28 |
WEIGHTED AVERAGE NUMBER OF SHARES | ||
Basic | 68,760 | 84,523 |
Diluted | 69,435 | 85,965 |
INMODE LTD. | ||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||
(U.S. dollars in thousands, except for per share data) | ||
(Unaudited) | ||
March 31, 2025 | December 31, 2024 | |
Assets | ||
CURRENT ASSETS: | ||
Cash and cash equivalents | 145,948 | 155,329 |
Marketable securities | 224,457 | 267,688 |
Short-term bank deposits | 142,520 | 173,455 |
Accounts receivable, net of allowance for credit losses | 32,367 | 36,335 |
Prepaid expense and other receivables | 25,564 | 22,097 |
Inventories | 63,781 | 59,548 |
TOTAL CURRENT ASSETS | 634,637 | 714,452 |
NON-CURRENT ASSETS: | ||
Accounts receivable, net of allowance for credit losses | 2,694 | 3,176 |
Deferred income tax asset | 55,338 | 56,285 |
Operating lease right-of-use assets | 9,133 | 8,732 |
Property and equipment, net | 2,233 | 2,322 |
Other investments | 700 | 700 |
TOTAL NON-CURRENT ASSETS | 70,098 | 71,215 |
TOTAL ASSETS | 704,735 | 785,667 |
Liabilities and shareholders' equity | ||
CURRENT LIABILITIES: | ||
Accounts payable | 15,052 | 13,782 |
Contract liabilities | 15,861 | 16,755 |
Other liabilities | 41,745 | 39,314 |
TOTAL CURRENT LIABILITIES | 72,658 | 69,851 |
NON-CURRENT LIABILITIES: | ||
Contract liabilities | 3,393 | 3,336 |
Other liabilities | 3,668 | 3,356 |
Operating lease liabilities | 5,588 | 5,311 |
TOTAL NON-CURRENT LIABILITIES | 12,649 | 12,003 |
TOTAL LIABILITIES | 85,307 | 81,854 |
TOTAL SHAREHOLDERS' EQUITY | 619,428 | 703,813 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 704,735 | 785,667 |
INMODE LTD. | |||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
(U.S. dollars in thousands, except for per share data) | |||
(Unaudited) | |||
Three months ended | |||
2025 | 2024 | ||
CASH FLOWS FROM OPERATING ACTIVITIES: | |||
Net income | 18,201 | 23,696 | |
Adjustments required to reconcile net income to net cash provided by | |||
Depreciation and amortization | 174 | 165 | |
Share-based compensation expenses | 2,518 | 3,983 | |
Change in allowance for credit losses of trade receivable | (94) | 187 | |
Loss (gains) on marketable securities, net | (2) | 29 | |
Finance income, net | (1,574) | (4,757) | |
Deferred income taxes, net | 896 | (37) | |
Changes in operating assets and liabilities: | |||
Decrease in accounts receivable | 4,544 | 9,308 | |
Increase in other receivables | (3,532) | (2,669) | |
Increase in inventories | (4,233) | (6,507) | |
Increase (decrease) in accounts payable | 1,270 | (743) | |
Decrease in other liabilities | (3,287) | (7,803) | |
Increase (decrease) in contract liabilities (current and non-current) | (837) | 9,262 | |
Net cash provided by operating activities | 14,044 | 24,114 | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||
Investment in short-term deposits | - | (31,297) | |
Proceeds from short-term deposits | 31,297 | - | |
Purchase of fixed assets | (85) | (112) | |
Purchase of marketable securities | (20,877) | (121,564) | |
Proceeds from sale of marketable securities | 3,003 | 13,465 | |
Proceeds from maturity of marketable securities | 62,147 | 92,118 | |
Net cash provided by (used in) investing activities | 75,485 | (47,390) | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Repurchase of ordinary shares | (99,960) | - | |
Exercise of options | 494 | 234 | |
Net cash provided by (used in) financing activities | (99,466) | 234 | |
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH | 556 | (439) | |
NET DECREASE IN CASH AND CASH EQUIVALENTS | (9,381) | (23,481) | |
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 155,329 | 144,411 | |
CASH AND CASH EQUIVALENTS AT END OF PERIOD | 145,948 | 120,930 |
INMODE LTD. | |||||
CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS | |||||
(U.S. dollars in thousands, except for per share data) | |||||
(Unaudited) | |||||
Three months ended | |||||
2025 | 2024 | ||||
Revenues by Category: | |||||
Capital Equipment revenues - United | 29,542 | 38 % | 30,859 | 38 % | |
Capital Equipment revenues - | 28,133 | 36 % | 26,923 | 34 % | |
Total Capital Equipment revenues | 57,675 | 74 % | 57,782 | 72 % | |
Consumables and service revenues | 20,199 | 26 % | 22,502 | 28 % | |
Total Revenue | 77,874 | 100 % | 80,284 | 100 % | |
Three months ended | ||||||
2025 | 2024 | |||||
% | % | |||||
United |
| Total | United | International | Total | |
Revenues by Technology: | ||||||
Minimally Invasive | 93 | 79 | 87 | 87 | 80 | 84 |
Hands-Free | 3 | 2 | 3 | 8 | 3 | 5 |
Non-Invasive | 4 | 19 | 10 | 5 | 17 | 11 |
100 | 100 | 100 | 100 | 100 | 100 |
INMODE LTD. | |||||||
RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF | |||||||
INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME | |||||||
(U.S. dollars in thousands, except for per share data) | |||||||
(Unaudited) | |||||||
Three months ended March 31, 2025 |
Three months ended March 31, 2024 | ||||||
GAAP |
Share Based |
Non-GAAP |
GAAP |
Share Based |
Non-GAAP | ||
REVENUES | 77,874 | - | 77,874 | 80,284 | - | 80,284 | |
COST OF REVENUES | 16,963 | (310) | 16,653 | 16,365 | (409) | 15,956 | |
GROSS PROFIT | 60,911 | 310 | 61,221 | 63,919 | 409 | 64,328 | |
OPERATING EXPENSES: | |||||||
Research and development | 2,895 | (222) | 2,673 | 3,518 | (428) | 3,090 | |
Sales and marketing | 39,727 | (1,763) | 37,964 | 39,795 | (2,883) | 36,912 | |
General and administrative | 2,671 | (223) | 2,448 | 2,514 | (263) | 2,251 | |
TOTAL OPERATING |
45,293 |
(2,208) |
43,085 |
45,827 |
(3,574) |
42,253 | |
OPERATIONS INCOME | 15,618 | 2,518 | 18,136 | 18,092 | 3,983 | 22,075 | |
Finance income, net | 6,859 | - | 6,859 | 7,984 | - | 7,984 | |
INCOME BEFORE INCOME TAXES | 22,477 | 2,518 | 24,995 | 26,076 | 3,983 | 30,059 | |
INCOME TAXES | 4,276 | (676) | 3,600 | 2,380 | - | 2,380 | |
NET INCOME | 18,201 | 3,194 | 21,395 | 23,696 | 3,983 | 27,679 | |
EARNINGS PER SHARE: | |||||||
Basic | 0.26 | 0.31 | 0.28 | 0.33 | |||
Diluted | 0.26 | 0.31 | 0.28 | 0.32 | |||
WEIGHTED AVERAGE NUMBER OF | |||||||
Basic | 68,760 | 68,760 | 84,523 | 84,523 | |||
Diluted | 69,435 | 69,611 | 85,965 | 86,563 |
Last Trade: | US$14.93 |
Daily Change: | -1.29 -7.95 |
Daily Volume: | 1,257,330 |
Market Cap: | US$1.140B |
March 03, 2025 February 04, 2025 September 04, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load